Breast Cancer Res Treat. 2013 Nov;142(1):89-99. doi: 10.1007/s10549-013-2710-z. Epub 2013 Oct 16.
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA).
Source
Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex, HA6 2RN, UK, david.miles@doctors.org.uk.
Abstract
Although the incidence of cancer increases with age, older patients are under-represented in cancer treatment trials, resulting in limited data availability in this patient population. Here we present results from pre-defined subgroup analyses conducted by age group (<65 0.31-0.86="" 0.52="" 0.53-0.80="" 0.65="" 127="" 60="" 65="" 67="" 808="" 95="" a="" according="" age.="" age="" analyses="" and="" appetite="" arm:="" arm="" assessed="" assigned="" asthenia="" be="" benefit="" biological="" both="" breast="" by="" cancer.="" cancer="" chemotherapy="" ci="" cleopatra="" clinicaltrials.gov="" combined="" compared="" data="" decreased="" diarrhoea="" docetaxel.="" docetaxel="" double-blind="" dysgeusia="" efficacy="" endpoint="" enrolled.="" experienced="" fatigue="" febrile="" for="" frequently="" from="" group.="" groups="" had="" her2-positive="" hr:="" iii="" in="" independently="" is="" less="" limited="" locally="" metastatic="" more="" nbsp="" nct00567190.="" neutropenia="" not="" of="" older="" or="" p="" patient="" patients.="" patients="" performed="" pertuzumab="" phase="" placebo-controlled="" placebo="" pre-specified="" previous="" primary="" progression-free="" randomized="" randomly="" received="" recurrent="" registered="" reported="" safety="" should="" study="" subgroup="" suggest="" survival.="" survival="" that="" the="" therapy="" those="" to="" trastuzumab="" treatment="" trial="" unresectable="" use="" vomiting="" vs="" was="" we="" were="" who="" with="" years:="" years="" younger="">
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου